Keyword: Dr. Patrick Soon-Shiong
The reduction, which amounts to about one-third of NantHealth’s headcount, will lower costs at the Patrick Soon-Shiong-helmed company.
NantCell has paid $13 million up front to license CytRx's orphan cancer drug aldoxorubicin.
Altor shareholders, revolting against Patrick Soon-Shiong's deal to buy the company, are going to court to block it.
Patrick Soon-Shiong's outfit NantCell will acquire Altor Bioscience for two bucks a share.
Patrick Soon-Shiong announced at ASCO that his biotech company wants to expand its cancer vaccine work.
Biotech billionaire Patrick Soon-Shiong has been through the media wringer in the last few months, so will welcome an FDA green light that will draw attention back to his immuno-oncology programs.
Patrick Soon-Shiong, CEO of NantKwest and NantWorks and founder of NantHealth, has come under increasing pressure from several media outlets in recent months, and this week he has taken to Twitter to fight back against those who have attacked him and his companies.
Viracta Therapeutics has closed a $18.4 million Series B round, with lead investor NantKwest also setting up a new midstage licensing deal.
As his inauguration nears, Donald Trump has interviewed an eclectic mix of candidates for his pick as National Institutes of Health (NIH) chief.
Dr. Patrick Soon-Shiong’s NantHealth and collaborators have begun a $20 million pediatric brain tumor sequencing project.